[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,945,896
  • Shares Outstanding, K 87,936
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,200 K
  • EBIT $ -201 M
  • EBITDA $ -213 M
  • 60-Month Beta 3.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.62

Options Overview Details

View History
  • Implied Volatility 75.62% (+0.35%)
  • Historical Volatility 60.07%
  • IV Percentile 16%
  • IV Rank 4.57%
  • IV High 222.63% on 09/16/25
  • IV Low 68.58% on 05/21/26
  • Expected Move (DTE 20) 9.90 (10.96%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 70
  • Volume Avg (30-Day) 347
  • Put/Call OI Ratio 4.03
  • Today's Open Interest 3,910
  • Open Int (30-Day) 6,424
  • Expected Range 80.46 to 100.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.80
  • Number of Estimates 5
  • High Estimate $-0.67
  • Low Estimate $-0.90
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) -433.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.45 +1.02%
on 08/28/26
110.18 -17.99%
on 08/19/26
-9.60 (-9.60%)
since 07/28/26
3-Month
68.50 +31.91%
on 06/02/26
110.18 -17.99%
on 08/19/26
+18.25 (+25.31%)
since 05/28/26
52-Week
14.51 +522.96%
on 09/22/25
110.18 -17.99%
on 08/19/26
+73.64 (+440.43%)
since 08/28/25

Most Recent Stories

More News
Stocks Finish Little Changed Ahead of Nvidia Earnings

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.05%....

INTU : 358.06 (+2.89%)
$SPX : 7,711.76 (-0.25%)
BSX : 46.84 (+0.36%)
SMMT : 13.73 (-4.19%)
DDOG : 236.98 (-2.45%)
ORCL : 150.85 (-0.72%)
NKE : 39.60 (+3.02%)
$IUXX : 29,433.43 (-0.70%)
NQU26 : 29,491.75s (-0.69%)
WMB : 73.73 (-0.62%)
SMTC : 131.17 (-7.91%)
QQQ : 716.43 (-0.65%)
Stocks Slip Ahead of Nvidia Earnings as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) is down by -0.02% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.10%. E-mini S&P futures...

INTU : 358.06 (+2.89%)
DDOG : 236.98 (-2.45%)
$IUXX : 29,433.43 (-0.70%)
ZNZ26 : 107-280s (-0.42%)
GDDY : 97.70 (+0.74%)
ESU26 : 7,722.00s (-0.26%)
SJM : 132.34 (+0.38%)
$DOWI : 53,559.99 (-0.02%)
LPLA : 370.69 (+2.62%)
SPY : 769.35 (-0.23%)
DIA : 535.06 (-0.03%)
$SPX : 7,711.76 (-0.25%)
Stocks Slightly Higher on Mixed US Economic News

The S&P 500 Index ($SPX ) (SPY ) is up by +0.04% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.01%. E-mini S&P futures (ESU26...

INTU : 358.06 (+2.89%)
$SPX : 7,711.76 (-0.25%)
BSX : 46.84 (+0.36%)
SMMT : 13.73 (-4.19%)
DDOG : 236.98 (-2.45%)
ORCL : 150.85 (-0.72%)
KSS : 17.50 (-3.58%)
$IUXX : 29,433.43 (-0.70%)
NQU26 : 29,491.75s (-0.69%)
SMTC : 131.17 (-7.91%)
QQQ : 716.43 (-0.65%)
CLV26 : 83.40s (-0.16%)
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints...

SYRE : 90.36 (-3.48%)
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints...

SYRE : 90.36 (-3.48%)
This Stock’s Already Up Nearly 600% Over the Past Year

Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum. Shares are trading at a new 3-year high. SYRE maintains a 100% “Buy” technical opinion from...

SYRE : 90.36 (-3.48%)
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT...

SYRE : 90.36 (-3.48%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation...

SYRE : 90.36 (-3.48%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation...

SYRE : 90.36 (-3.48%)
Spyre Therapeutics: Q2 Earnings Snapshot

Spyre Therapeutics: Q2 Earnings Snapshot

SYRE : 90.36 (-3.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based...

See More

Key Turning Points

3rd Resistance Point 96.62
2nd Resistance Point 95.01
1st Resistance Point 92.68
Last Price 90.36
1st Support Level 88.74
2nd Support Level 87.13
3rd Support Level 84.80

See More

52-Week High 110.18
Last Price 90.36
Fibonacci 61.8% 73.63
Fibonacci 50% 62.34
Fibonacci 38.2% 51.05
52-Week Low 14.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.